This bill establishes new provisions regarding non-opioid treatments within group insurance plans in Oklahoma. It defines key terms such as "group insurance plan," "health care prescriber," "insurer," and "non-opioid treatment." The bill authorizes insurers to amend their preferred drug lists (PDLs) and mandates that non-opioid drugs approved by the United States Food and Drug Administration (FDA) for pain management must not be disadvantaged compared to opioid medications. It also allows for the inclusion of non-opioid drugs in the PDL immediately upon FDA approval, regardless of prior review by the insurer.

Additionally, the bill requires insurers to provide reimbursement to health care prescribers for non-opioid treatments administered to covered employees and ensures that hospitals are reimbursed separately for non-opioid treatments provided as part of inpatient or outpatient services. The effective date for this legislation is set for November 1, 2025.